SCHEDULE: FMR LLC Holds 9.4% Stake in Relay Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 9.4% of Relay Therapeutics' common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, collectively beneficially own 20,015,113.24 shares of Relay Therapeutics Inc. common stock.
• This holding represents 9.4% of the class of securities.
• The filing is a Schedule 13G, indicating passive investment by FMR LLC.
• The reporting date for this ownership stake is June 30, 2026.
• FMR LLC is identified as a holding company, and Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but stable institutional holding without immediate catalysts for dramatic price movement.

Positives

• Significant institutional ownership by a major financial entity (FMR LLC) can provide a degree of stability to the stock.
• The filing confirms FMR LLC's role as a substantial, albeit passive, investor.

Negatives

• The filing does not contain any new financial performance data or strategic updates, making it purely an ownership disclosure.
• The passive nature of the holding means it's unlikely to drive significant strategic changes or immediate price appreciation.

Risks

• While FMR LLC's holding is passive, any future change in their investment strategy could impact the stock price.
• The filing does not provide insights into Relay Therapeutics' operational performance or future prospects, which are the primary drivers of stock value.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership and does not contain forward-looking statements or guidance from Relay Therapeutics Inc.

Management Comments

• FMR LLC and Abigail P. Johnson, through various entities, beneficially own 20,015,113.24 shares, representing 9.4% of the common stock.
• The filing is made in accordance with Rule 13d-1(b) and certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Industry Context

StockSavvy.ai notes that significant institutional holdings, as reported in Schedule 13G filings, are common in the biotechnology sector. These filings indicate substantial investor confidence but do not necessarily reflect the company's operational performance or pipeline progress.

Stakeholder Impact

• Shareholders: The significant holding by FMR LLC may be perceived as a positive signal of institutional support, potentially contributing to stock stability.
• Management: The passive nature of the holding suggests FMR LLC is unlikely to exert direct influence on day-to-day management decisions unless their stake changes significantly.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their shares in Relay Therapeutics Inc.
• Future filings will be made if there are material changes in beneficial ownership.

Key Dates

Keywords

Relay Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership